Clomid in Men: This study aims to investigate whether men with low testosterone due to altered brain regulation of male hormone function who have previously been treated with testosterone may respond in the same way as men who have not been so treated to clomiphene citrate, an agent usually used in female infertility, which has been shown to improve the secretion of male hormones in some cases.
Detailed description clomid in men
Clomiphene, an FDA-approved oral drug for the treatment of female infertility, has been shown to normalize testosterone levels in men with hypogonadotropic hypogonadism. It seems to be safe and well tolerated. This study will compare the response of testosterone to clomiphene citrate in men. Veterans with previously untreated hypothalamic hypogonadism with responses from similar patients already treated with injectable or transdermal testosterone. This is an open, prospective, interventional study that will be conducted in an outpatient specialized medical facility.
Parameter. We will randomize 64 veteran hypogonadal males, equally divided between naive and previous treatment, to be treated with Clomid for 8 weeks, increasing the initial dose from 25 mg to 50 mg/day in those who fail to achieve target testosterone levels (450 ng/dL).
After the first 3 weeks. Endpoint measurements performed in the Phoenix VA Health Care System (PVAHCS) clinical laboratory will be total testosterone as well as bioavailable testosterone and sex hormone binding globulin. Total testosterone levels will be reported after 8 weeks of treatment. as the primary endpoint. Safety measures (complete blood count, liver function, PSA) will be assessed at 8 points. weeks also. This study will help guide the design of future studies of clomiphene in men with hypogonadism.